Biophysical Characterization

Comprehensive biophysical analysis 

We utilize orthogonal approaches to provide a holistic view of your therapeutic candidates. This allow us to assess critical quality attributes (CQAs) that are essential for therapeutic efficacy, such as: 

‍Structural Analysis 

• Secondary and tertiary structure determination 
• Conformational stability assessment 
• Molecular weight and size distribution analysis 

Stability and Formulation Assessment 

• Thermal and colloidal stability assessments 
• Aggregation propensity studies 
• Formulation optimization support 

‍Tailored solutions for diverse therapeutic modalities 

Our modality and disease-agnostic approach allows us to provide comprehensive biophysical characterization support for a wide range of therapeutic modalities, including: 

‍Peptides, Proteins, Antibodies, ADCs, TPDs and oligonucleotides 

• Secondary and tertiary structure analysis 
• Stability assessments under various conditions 
• Binding specificity and off-target interaction studies 
• Epitope mapping 

Viral and Non-viral Vectors including LNPs 

• Particle size and distribution analysis 
• Surface charge measurements 
• Payload encapsulation efficiency determination 
• Vector-target cell interaction studies 

Advancing drug discovery through biophysical insights 

By leveraging our comprehensive biophysical characterization capabilities, we help our partners: 

‍Accelerate lead optimization: Rapidly identify and prioritize promising candidates based on their biophysical properties, thereby streamlining the drug discovery process

• Optimize biologic stability: Assess and enhance the stability of therapeutic candidates under various environmental conditions, ensuring longer shelf-life and maintained efficacy
• Improve formulation strategies: Develop stable formulations that preserve the activity of complex biologics and delivery systems
• Support regulatory compliance: Generate robust data packages that align with regulatory requirements for diverse therapeutic modalities
• Mitigate development risks: Early identification of potential issues related to aggregation or misfolding allows for timely interventions, reducing the risk of product failure during clinical development

Our extensive expertise and advanced instrumentation, means the biophysical sciences team can design custom workflows to support effective translation of diverse therapeutic modalities from early biologics discovery to candidate selection. A comprehensive approach ensures thorough characterization, enabling informed decision-making throughout the drug discovery process.